Modality
ERT
MOA
PLK4i
Target
EZH2
Pathway
Ferroptosis
ObesityHNSCCAlzheimer's
Development Pipeline
Preclinical
Feb 2020
→ Feb 2028
PreclinicalCurrent
NCT05306778
1,962 pts·Alzheimer's
2022-10→TBD·Completed
NCT06838266
1,255 pts·HNSCC
2020-02→2028-02·Recruiting
3,217 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-02-051.9y awayInterim· HNSCC
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
Preclinical
Recruit…
Preclinical
Complet…
Catalysts
Interim
2028-02-05 · 1.9y away
HNSCC
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05306778 | Preclinical | Alzheimer's | Completed | 1962 | PANSS |
| NCT06838266 | Preclinical | HNSCC | Recruiting | 1255 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Liravorutinib | Biomea Fusion | Phase 1/2 | GPRC5D | |
| Voxabrutinib | Annexon | Phase 1/2 | EZH2 | |
| SLD-1824 | Solid Bio | Phase 2 | EZH2 | |
| CSL-7919 | CSL Limited | Preclinical | BTK | |
| Gelibrutinib | Sun Pharma | NDA/BLA | EZH2 | |
| Rimatuximab | Boehringer Ingelheim | Phase 2/3 | PLK4 |